Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer

In this issue of The Oncologist, Agarwal et al. report negative results from a phase I trial of LFA102. Although “negative” in terms of antitumor activity, the study provides useful pharmacokinetic and pharmacodynamic information. Future trials evaluating PRLR blockers alone and in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Sullivan, Ciara C., Bates, Susan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861375/
https://www.ncbi.nlm.nih.gov/pubmed/27107001
http://dx.doi.org/10.1634/theoncologist.2016-0108
_version_ 1782431210766598144
author O’Sullivan, Ciara C.
Bates, Susan E.
author_facet O’Sullivan, Ciara C.
Bates, Susan E.
author_sort O’Sullivan, Ciara C.
collection PubMed
description In this issue of The Oncologist, Agarwal et al. report negative results from a phase I trial of LFA102. Although “negative” in terms of antitumor activity, the study provides useful pharmacokinetic and pharmacodynamic information. Future trials evaluating PRLR blockers alone and in combination with other agents may still be warranted in patients with breast and prostate cancer.
format Online
Article
Text
id pubmed-4861375
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-48613752016-05-16 Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer O’Sullivan, Ciara C. Bates, Susan E. Oncologist Commentary In this issue of The Oncologist, Agarwal et al. report negative results from a phase I trial of LFA102. Although “negative” in terms of antitumor activity, the study provides useful pharmacokinetic and pharmacodynamic information. Future trials evaluating PRLR blockers alone and in combination with other agents may still be warranted in patients with breast and prostate cancer. AlphaMed Press 2016-05 2016-04-22 /pmc/articles/PMC4861375/ /pubmed/27107001 http://dx.doi.org/10.1634/theoncologist.2016-0108 Text en ©AlphaMed Press
spellingShingle Commentary
O’Sullivan, Ciara C.
Bates, Susan E.
Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer
title Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer
title_full Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer
title_fullStr Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer
title_full_unstemmed Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer
title_short Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer
title_sort targeting prolactin receptor (prlr) signaling in prlr-positive breast and prostate cancer
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861375/
https://www.ncbi.nlm.nih.gov/pubmed/27107001
http://dx.doi.org/10.1634/theoncologist.2016-0108
work_keys_str_mv AT osullivanciarac targetingprolactinreceptorprlrsignalinginprlrpositivebreastandprostatecancer
AT batessusane targetingprolactinreceptorprlrsignalinginprlrpositivebreastandprostatecancer

Ejemplares similares